Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Assets (2019 - 2025)

Immunocore Holdings' Assets history spans 4 years, with the latest figure at $1.1 billion for Q3 2025.

  • For Q3 2025, Assets rose 1.65% year-over-year to $1.1 billion; the TTM value through Sep 2025 reached $1.1 billion, up 1.65%, while the annual FY2024 figure was $1.0 billion, 69.1% up from the prior year.
  • Assets for Q3 2025 was $1.1 billion at Immunocore Holdings, up from $1.1 billion in the prior quarter.
  • Across five years, Assets topped out at $1.1 billion in Q3 2025 and bottomed at $526.8 million in Q4 2022.
  • The 4-year median for Assets is $1.0 billion (2024), against an average of $938.7 million.
  • The largest annual shift saw Assets surged 69.1% in 2024 before it increased 1.65% in 2025.
  • A 4-year view of Assets shows it stood at $526.8 million in 2022, then rose by 13.33% to $597.0 million in 2023, then soared by 69.1% to $1.0 billion in 2024, then rose by 9.21% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Assets are $1.1 billion (Q3 2025), $1.1 billion (Q2 2025), and $1.0 billion (Q1 2025).